Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jul 18;104(29):e43048.
doi: 10.1097/MD.0000000000043048.

The supplementary value of the neutrophil-to-lymphocyte ratio in the diagnosis of rheumatoid arthritis

Affiliations
Observational Study

The supplementary value of the neutrophil-to-lymphocyte ratio in the diagnosis of rheumatoid arthritis

Xiaolan Yang. Medicine (Baltimore). .

Abstract

To investigate the supplementary value of the neutrophil-to-lymphocyte ratio (NLR) in diagnosing rheumatoid arthritis (RA) and assessing disease activity, particularly in seronegative RA. This retrospective single-center study included 304 patients from the Department of Rheumatology and Immunology at a tertiary hospital between February 2021 and February 2024. The RA group consisted of 201 patients, and the non-RA control group had 103 patients. Demographic characteristics, blood tests, inflammatory markers (C-reactive protein, erythrocyte sedimentation rate), autoantibodies (rheumatoid factor, anti-cyclic citrullinated peptide antibody), and clinical evaluation data (Disease Activity Score in 28 Joints score) were collected. Multivariate logistic and ordinal logistic regression analyses were performed to identify RA-related factors. The combined diagnostic benefit of NLR was assessed using area under the receiver operating characteristic curve (AUC), net reclassification improvement, and integrated discrimination improvement. Among the 304 subjects, 201 were RA patients (mean age 52.3 ± 11.8 yr, 78.6% female) and 103 were non-RA controls (mean age 50.6 ± 10.2 yr, 73.8% female). The NLR in the RA group was significantly higher than in the non-RA group (3.2 [2.1-4.8] vs 1.8 [1.2-2.3], P < .001). Multivariate regression analysis showed that NLR was an independent predictor for RA diagnosis (odds ratio = 2.15, 95% confidence interval: 1.62-2.85, P < .001), with better diagnostic performance than C-reactive protein and erythrocyte sedimentation rate. In seronegative RA patients, NLR remained significantly diagnostic (odds ratio = 2.01, 95% confidence interval: 1.20-3.37, P = .008). NLR positively correlated with disease activity and was higher in moderate-to-high activity patients (4.2 [3.2-5.5], P < .001). Incremental analysis showed that NLR improved model performance: in the RA population, AUC increased from 0.89 to 0.94 (ΔAUC = 0.05, P < .001), and in seronegative RA, AUC increased from 0.72 to 0.82 (P = .002). For disease activity prediction, AUC increased from 0.85 to 0.91 (ΔAUC = 0.06, P = .004), with significant improvements in net reclassification improvement and integrated discrimination improvement (0.18 and 0.07, respectively). NLR is an independent predictor for diagnosing RA and assessing disease activity, particularly in seronegative RA. It enhances diagnostic sensitivity and model discriminative ability and should be promoted as a key inflammatory biomarker for early RA diagnosis.

Keywords: diagnostic value; disease activity; inflammatory markers; neutrophil-to-lymphocyte ratio; rheumatoid arthritis; seronegative rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The author has no funding and conflicts of interest to disclose.

Similar articles

References

    1. Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18:591–602. - PubMed
    1. GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e594–610. - PMC - PubMed
    1. Lin H, Xie Y, Wei X, Wei C, Li Z, Hu F. Anti-citrullinated procollagen C-endopeptidase enhancer antibody: a potential biomarker for seronegative rheumatoid arthritis. Rheumatology (Oxford). 2025;64:246–52. - PubMed
    1. De Stefano L, Bozzalla Cassione E, Sammali Y, et al. High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis. Rheumatology (Oxford). 2025;64:2461–8. - PubMed
    1. Balaji D, Mohanasundaram K, Gopalakrishnan KV, Suthakaran PK. Anti-carbamylated protein antibodies positivity in rheumatoid arthritis and its association with rheumatoid factor and anti-cyclic citrullinated protein antibodies. Cureus. 2024;16:e63652. - PMC - PubMed

Publication types